Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data

 April 15, 2026

BioSpace

The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.

RegulatoryMetabolic & GLP-1Read full story

Post navigation

Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico →
← Amazon launches its AI drug discovery platform

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com